tiprankstipranks
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
US Market

Karyopharm Therapeutics (KPTI) Income Statement

Compare
1,168 Followers

Karyopharm Therapeutics Income Statement

Last quarter (Q4 2024), Karyopharm Therapeutics's total revenue was $30.54M, a decrease of -9.50% from the same quarter last year. In Q4, Karyopharm Therapeutics's net income was $-30.78M. See Karyopharm Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 145.24M$ 146.03M$ 157.07M$ 209.82M$ 108.08M
Gross Profit
$ 139.23M$ 141.09M$ 151.86M$ 206.42M$ 105.38M
Operating Expenses
$ 258.67M$ 270.63M$ 294.06M$ 304.69M$ 277.23M
Depreciation and Amortization
$ 340.00K$ 530.00K$ 621.00K$ 789.00K$ 972.00K
EBITDA
$ -38.60M$ -118.42M$ -139.31M$ -96.98M$ -167.85M
Operating Income
$ -119.44M$ -129.54M$ -142.20M$ -98.27M$ -171.85M
Other Income/Expenses
$ 43.08M$ -13.24M$ -22.72M$ -25.55M$ -24.11M
Pretax Income
$ -76.36M$ -142.78M$ -164.92M$ -123.82M$ -195.96M
Net Income
$ -76.42M$ -143.10M$ -165.29M$ -124.09M$ -196.27M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -0.63$ -1.25$ -2.02$ -1.65$ -2.72
Diluted EPS
$ -0.60$ -1.25$ -2.02$ -1.65$ -2.72
Weighted Average Shares Outstanding
121.86M 114.22M 81.87M 75.22M 72.04M
Weighted Average Shares Outstanding (Diluted)
126.81M 114.22M 81.87M 75.22M 72.04M
Currency in USD

Karyopharm Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis